GlassScriptPhysician profile
Laura J Slone
NPI 1093001372
$1,227.29
in general payments reported to CMS, 2019-2025
23 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $69.83 · 2021: $27.13 · 2022: $179 · 2023: $270 · 2024: $134 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.31 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.95 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $192.66 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $82.53 | 2023-2024 | Acessa Provu System, Omni Hysteroscope, Myosure Tissue Removal Device |
| Mayne Pharma Commercial LLC | $69.90 | 2022-2023 | |
| Biogen, INC. | $69.32 | 2025 | Zurzuvae |
| Aspira Women'S Health INC | $64.74 | 2022 | |
| Pfizer INC. | $63.81 | 2022-2024 | |
| Ascend Therapeutics US, LLC | $38.48 | 2019 | |
| Sumitomo Pharma America, INC. | $35.73 | 2023-2024 | Myfembree |
| Merck Sharp & Dohme LLC | $33.96 | 2023 | Gardasil 9 |
| Amgen INC. | $33.13 | 2019 | |
| Organon LLC | $28.72 | 2023-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $28.69 | 2019-2021 | |
| Smith+Nephew, INC. | $28.52 | 2025 | Pico 7, Pico 14 |
| Evofem Biosciences, INC. | $24.19 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21.77 | 2019 | |
| Duchesnay USA Incorporated | $17.71 | 2019 | |
| Myovant Sciences INC. | $16.24 | 2022 | |
| Shield Therapeutics INC | $16.13 | 2025 | |
| Therapeuticsmd, INC. | $15.55 | 2020 | |
| Meditrina | $14.84 | 2023 | |
| Exeltis, USA INC. | $14.53 | 2023 | Slynd |
| Novo Nordisk INC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Slone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.